ABSTRACT G protein-coupled receptor 84 (GPR84) is a free fatty acid receptor activated by medium-chain free fatty acids with 9-14 carbons. It is expressed mainly in the immune-related tissues, such as spleen, bone marrow, and peripheral blood leukocytes. GPR84 plays significant roles in inflammatory processes and may represent a novel drug target for the treatment of immune-mediated diseases. However, the lack of potent and specific ligands for GPR84 hindered the study of its functions and the development of potential clinical applications. Here, we report the screen of 160,000 smallmolecule compounds with a calcium mobilization assay using a human embryonic kidney 293 cell line stably expressing GPR84 and Ga16, and the identification of 2-(hexylthio)pyrimidine-4,6-diol (ZQ-16) as a potent and selective agonist of GPR84 with a novel structure. ZQ-16 activates several GPR84-mediated signaling pathways, including calcium mobilization, inhibition of cAMP accumulation, phosphorylation of extracellular signal-regulated protein kinase 1/2, receptor desensitization and internalization, and receptor-b-arrestin interaction. This compound may be a useful tool to study the functions of GPR84 and a potential candidate for further structural optimization.
Introduction
Free fatty acids (FFAs) are essential nutrients. An everincreasing number of studies have also demonstrated that FFAs are important signaling molecules contributing to many cellular functions. In the past 15 years, FFAs have been found to activate several G protein-coupled receptors (GPCRs), which are named free fatty acid receptors (FFARs), including G protein-coupled receptor 40 [GPR40 (FFAR1)], GPR41 (FFAR3), GPR43 (FFAR2), GPR84, GPR119, and GPR120 (FFAR4) (Brown et al., 2003; Itoh et al., 2003; Hirasawa et al., 2005; Piomelli, 2005; Wang et al., 2006) . These FFARs are categorized based on the chain length of their FFA ligands, and they have been demonstrated to play important physiologic and pathologic roles (Oh and Lagakos, 2011; Talukdar et al., 2011) .
GPR84 was among a group of orphan GPCRs originally discovered by an expressed sequence tag data mining strategy. It belongs to the rhodopsin family of GPCRs and contains a number of conserved motifs (Wittenberger et al., 2001) . GPR84 is activated by medium-chain FFAs (MCFAs) with 9-14 carbons (Wang et al., 2006) . It is expressed mainly in the immune-related tissues, such as thymus, spleen, bone marrow, and peripheral blood leukocytes, and is significantly upregulated in monocytes/macrophages upon lipopolysaccharide (LPS) stimulation (Wang et al., 2006) . In activated T cells, GPR84 has been found to regulate early interleukin 4 (IL-4) gene expression. Knockout of GPR84 in T cells leads to augmented IL-4 production (Venkataraman and Kuo, 2005) . In monocytes/macrophages, MCFAs have been demonstrated to act through GPR84 to amplify LPS-stimulated production of the proinflammatory cytokine IL-12 p40 (Wang et al., 2006) . In animal models of endotoxemia and multiple sclerosis (experimental autoimmune encephalomyelitis), GPR84 is upregulated in microglia, suggesting that GPR84 may regulate the processes of neural inflammation (Bouchard et al., 2007) . GPR84 has also been shown to emerge in adipocytes in response to tumor necrosis factor a secreted by the infiltrating macrophages, and activation of this receptor by MCFAs enhances the inhibitory effect of tumor necrosis factor a on adiponectin expression in adipocytes, suggesting that GPR84 may exacerbate obesity-associated insulin resistance (Nagasaki et al., 2012) . It has also been demonstrated that GPR84 in zebrafish is involved in the accumulation of intracellular lipid droplets, and undecanoic acid can enhance LPS-induced IL-12 p40 production through GPR84 in zebrafish, indicating that GPR84 is a direct factor bridging fatty acid metabolism and immunologic regulation (Huang et al., 2014) .
In 2006, Wang et al. succeeded in deorphanizing GPR84 and demonstrated that MCFAs, with carbon chain lengths of 9-14, are native ligands of GPR84. Lauric acid (C12), undecanoic acid (C11), and capric acid (C10) are the most potent endogenous agonists of GPR84 currently known (Wang et al., 2006) . GPR84 can also be activated by two small molecules, diindolylmethane (Nikaido et al., 2015) and 6-n-octylaminouracil (6-OAU) (Suzuki et al., 2013) . However, the potency and selectivity of these ligands are limited, which might have hindered the study of receptor functions and the development of potential clinical applications.
In this study, we carried out a high-throughput screening of 160,000 small-molecule compounds on GPR84 and identified 2-(hexylthio)pyrimidine-4,6-diol (ZQ-16) as a potent and selective GPR84 agonist.
Materials and Methods
Reagents. Mammalian expression vectors encoding human GPR84 and Ga16 were purchased from the University of MissouriRolla cDNA Resource Center (Rolla, MO). Human embryonic kidney 293 (HEK293) cells were obtained from American Type Culture Collection (Manassas, VA). Dulbecco's modified Eagle's medium (DMEM) and Fluo-4 AM were purchased from Invitrogen (Carlsbad, CA). Sulfinpyrazone, forskolin, and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma-Aldrich (St. Louis, MO). Homogeneous time-resolved fluorescence (HTRF) cAMP dynamic 2 assay kits were purchased from Cisbio (Codolet, France). Screening compounds were obtained from the Chinese National Compound Library (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China). Compound ZQ-16 was purchased from ChemDiv (San Diego, CA).
Cell Culture and Transfection. HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 mg/l penicillin, and 100 mg/l streptomycin at 37°C in a moist incubator supplied with a 5% CO 2 atmosphere. For transient transfection, approximately 1 Â 10 6 cells were mixed with 1-2 mg of plasmids in 200 ml of transfection buffer, and electroporation was performed with a Scientz-2C electroporation apparatus (Scientz Biotech, Ningbo, China). To generate HEK293 cell lines stably expressing GPR84 and Ga16, the transfected cells were seeded onto 10-cm dishes, and antibiotics including G418 (400 mg/ml) and blasticidin (20 mg/ml) were added to the culture medium the next day. The selection medium was changed every 3 days until the formation of colonies. Single colonies were selected, expanded, and tested for the expression of the transfected genes.
Calcium Mobilization Assay. HEK293 cells stably expressing GPR84 (or other GPCRs) and Ga16 were seeded onto 96-well plates at a density of 4 Â 10 4 cells/well and cultured overnight. The culture medium was then changed to Hanks' balanced salt solution (HBSS) buffer containing 2 mM Fluo-4 AM and 250 mM sulfinpyrazone and incubated at 37°C for 45 minutes. After removal of the excess dye, the cells were rinsed with HBSS once. In the antagonist or desensitization mode, cells were pretreated with 50 ml of HBSS containing compounds of interest or 1% dimethylsulfoxide (DMSO; negative control) for 10 minutes. Then 25 ml of agonists were dispensed into the well with an FDSS 7000EX microplate reader (Hamamatsu, Bridgewater, NJ), and intracellular calcium change was recorded with an excitation wavelength of 485 nm and emission wavelength of 525 nm. In the agonist mode, 50 ml of HBSS was added to the dye-loaded cells, and 25 ml of HBSS containing compounds of interest or 1% DMSO (negative control) was added with FDSS 7000EX, and calcium change was measured.
High-Throughput Screening of 160,000 Compounds. Using a calcium mobilization assay, all compounds were screened using the antagonist mode at a concentration of 20 mM in 384-well plates, and intracellular calcium change was detected by FDSS 7000EX. In each plate, 16 wells were pretreated with 1 mM 6-OAU and used as positive controls, and another set of 16 wells were pretreated with 1% DMSO and set as negative controls. The intracellular calcium changes were normalized to 100 and 0% in the wells pretreated with DMSO and 6-OAU, respectively. Compounds causing intracellular calcium levels to reduce to less than 30% were considered as "hits" in the primary screening. Then the hits were further tested in the agonist mode of the calcium assay to confirm whether they were agonists or antagonists.
HTRF cAMP Assay. Intracellular cAMP levels were detected with an HTRF cAMP kit obtained from Cisbio, according to the manufacture's instructions. In brief, cells were harvested and resuspended in phosphate-buffered saline (PBS) containing 500 mM IBMX to obtain a final cell count of 4 Â 10 5 cells/ml. The cells were dispensed into 384-well plates at 2000 cells/5 ml/well. Then 2.5 ml of buffer containing compounds of interest at various concentrations was added to the plates. After incubation at room temperature for 30 minutes, 2.5 ml of PBS containing 10 mM forskolin was added, and the incubation was continued for another 30 minutes. Lysis buffer containing anticAMP antibody and d2-cAMP (a fluorescent conjugated cAMP) was added to stop the reaction. After 60-minute incubation in the dark, HTRF signals were detected with an Envision 2101 plate reader (PerkinElmer, Waltham, MA).
Western Blot. Cells were serum starved for 4 hours and then treated with compounds for 5 minutes at 37°C. The cells were then lysed, sonicated, and boiled at 95°C for 5 minutes in sample buffer (62.5 mM Tris-HCl, 2% sodium dodecyl sulfate, 10% glycerol, 50 mM dithiothreitol, and 0.01% bromophenyl blue, pH 6.8). Aliquots of protein were fractionated by SDS-PAGE on 10% polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA). After blocking, the membranes were incubated overnight in buffer containing antibodies against glyceraldehyde-3-phosphate dehydrogenase, extracellular signal-regulated protein kinase 1/2 (ERK1/2), or phosphorylated ERK1/2 (Cell Signaling Technology, Danvers, MA) at 4°C. The next day, the membranes were washed and incubated with proper secondary antibodies conjugated to horseradish peroxidase for 1 hour. After the final wash, immunostaining was visualized with the Amersham ECL Plus reagents (GE Healthcare, Piscataway, NJ), and images were captured and analyzed with the ChemiDoc Imaging Station (Bio-Rad, Hercules, CA).
Receptor Internalization Assay. HEK293 cells transfected with plasmids encoding GPR84-green fluorescent protein (GFP) were seeded onto a 96-well plate with a glass bottom. Twenty-four hours later, cells were changed into DMEM medium containing compounds of interest or 0.1% DMSO and incubated for different durations. Cells were then washed with PBS and fixed in 4% paraformaldehyde. After counterstaining of nuclei with Hoechst dye 33342, fluorescent images were obtained with Operetta (PerkinElmer).
GPCR-b-Arrestin Interaction Assay. A split luciferase complementation assay was used to test whether ZQ-16 induces interaction Discovery of New GPR84 Agonist between GPR84 and b-arrestin2, as previously reported (Hida et al., 2009; Hattori et al., 2013) . In brief, HEK293 cells seeded at 4 Â 10 4 cells/well on 96-well plates were cotransfected with plasmids encoding Emerald luciferase (ELuc)N-terminus-b-arrestin2 with GPR84-ELuc C-terminus or empty vector. Twenty-four hours later, cells were changed into DMEM medium containing compounds of interest at various concentrations, and incubated at 37°C for 20 minutes. The luciferase activity was then evaluated with Emerald Luc Luciferase assay reagent according to the manufacturer's protocol (Toyobo, Osaka, Japan). Bioluminescence was measured with an Envision 2101 plate reader (PerkinElmer).
Statistical Analysis. Data were analyzed with GraphPad Prism software (GraphPad, La Jolla, CA). Nonlinear regression analysis was performed to generate dose-response curves and calculate EC 50 and IC 50 values. The data are presented as means 6 S.E.M. Two-tailed Student's t tests were performed, and P , 0.05 was considered to be statistically significant.
Results
Development of a Cell-Based Screen System for the Discovery of GPR84 Ligands. To search for new GPR84-specific ligands, we established a HEK293 cell line stably expressing the HA (hemagglutinin)-GPR84 and Ga16 proteins. Ga16 belongs to the Gaq subfamily of G proteins and can couple to many GPCRs to induce calcium mobilization upon receptor activation (Coward et al., 1999; Cabrera-Vera et al., 2003; Zhu et al., 2008) , and is thus commonly used in screening assays for GPCR ligands. As shown in Fig. 1A (top) , GPR84 was clearly detectable with an anti-HA antibody on the cell surface of the HEK293/Ga16/GPR84 cell line and not observed in the parental HEK293/Ga16 cells (Fig. 1A, bottom) . 6-OAU, a previously reported agonist of GPR84 (Suzuki et al., 2013) , evoked a dose-dependent increase in intracellular calcium concentrations in HEK293/Ga16/GPR84 cells, with an EC 50 value of 1.01 6 0.06 mM (Fig. 1B) , but not in the HEK293/Ga16 cells transfected with empty vector.
To discover both GPR84 agonists and antagonists in one primary screen, we designed a two-step protocol. It is easy to understand that an antagonist will block agonist induced signaling. As a matter of fact, an agonist may also display an antagonist-type blockade effect due to receptor desensitization. Receptor desensitization is a general mechanism that leads to the loss of GPCR function after repetitive agonist stimulation (Pierce et al., 2002; Ritter and Hall, 2009; Calebiro et al., 2010) . We first tested GPR84 desensitization with 6-OAU. The HEK293/Ga16/GPR84 cells were pretreated with various concentrations of the agonist 6-OAU for 10 minutes, and then restimulated with 6-OAU (3 mM). As demonstrated in Fig. 1C , pretreatment of agonist 6-OAU induced a dosedependent decrease of the calcium signal evoked by the 3 mM 6-OAU. Enlightened by this, we designed a two-step protocol (Fig. 1D) . In step 1, primary screen in the antagonist mode, cells are pretreated with test compounds and then restimulated with Representative western blot analysis of ERK1/2 phosphorylation (pERK1/2) in HEK293/GPR84 cells (A) or HEK293 cells transfected with empty vector (B) stimulated with DMSO (1%, vehicle control), PMA (phorbol-12-myristate-13-acetate) (10 mM, positive control), 6-OAU (10 mM), and ZQ-16 (10 mM) for 5 minutes. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
3 mM 6-OAU. Compounds that block the signal of 6-OAU may include true antagonists and agonists that induce receptor desensitization. In step 2, secondary screen in the agonist mode, the compounds that block the signal of 6-OAU are used to stimulate HEK293/Ga16/GPR84 directly, and agonists evoke calcium response while antagonists have no effect. Thus, with these two simple steps, we can identify both GPR84 agonists and antagonists in one high-throughput screen.
High-Throughput Screening and Identification of ZQ-16 as a Novel and Selective GPR84 Agonist. With the HEK293/Ga16/GPR84 cell lines, approximately 160,000 compounds from the Chinese National Compound Library were screened in duplicate at 20 mM concentration in the antagonist mode of the calcium mobilization assay, and representative primary screen results are presented ( Fig. 2A) . Then, compounds showing $70% inhibition of the calcium signal evoked by 6-OAU were selected and further tested in the agonist mode. Finally, only one compound, designated as ZQ-16, induced calcium elevation to a similar level as the reported agonist 6-OAU (Fig. 2B) . ZQ-16 contains a 2-mercaptopyrimidine-4,6-diol core (Fig. 2C) , which may represent a new class of GPR84 agonist. Since compound collections are not inherently stable, new ZQ-16 was purchased from ChemDiv and used for the further characterizations. Compound ZQ-16 was found to induce calcium response in a dose-dependent manner, with an EC 50 value of 0.213 6 0.042 mM (Fig. 2D) , which is approximately 6-fold more potent than the reported agonist 6-OAU (EC 50 5 1.25 6 0.19 mM).
FFARs may share some ligands. For example, GPR40 and GPR120 are both activated by medium-and long-chain FFAs, and GPR119 is also activated by long-chain FFAs. GPR84 is activated by medium-chain FFAs, whereas GPR41 and GPR43 are activated by short-chain FFAs (Talukdar et al., 2011) . To assess whether ZQ-16 is a specific agonist for GPR84, we tested its agonist activity on other FFARs. As demonstrated in Table 1 , ZQ-16 did not evoke calcium responses in HEK293 cells expressing other FFARs, including GPR40, GPR41, GPR119, and GPR120, at concentrations up to 100 mM. These receptors were functional, since they could be activated by reported ligands with EC 50 values comparable to published data (Briscoe et al., 2003; Xiong et al., 2004; Overton et al., 2006; Shimpukade et al., 2012; Hudson et al., 2013; Suzuki et al., 2013; Song et al., 2015) . These results indicate that ZQ-16 is a selective agonist for GPR84. Fig. 5 . ZQ-16 induces GPR84 desensitization. (A) HEK293/Ga16/GPR84 cells were loaded with Fluo-4 AM and stimulated (first arrow) with 6-OAU (10 mM, positive control), ZQ-16 (10 mM), or DMSO (1%, negative control), and intracellular calcium was measured. Ten minutes later, cells were washed and restimulated (second arrow) with agonist 6-OAU (10 mM), and intracellular calcium levels were measured. Representative calcium signals are presented. (B) Statistical analysis of the calcium peak value presented in (A). Data are the means 6 S.E.M. (n = 3). ***P , 0.001 versus DMSO (first white bar). ### P , 0.001 versus DMSO prestimulated group (second white bar). RFU, relative fluorescence units. Fig. 6 . ZQ-16 induces GPR84 internalization. HEK293 cells transfected with GPR84-GFP were treated with DMSO (0.1%, negative control), 6-OAU (10 mM, positive control), or ZQ-16 (10 mM) for indicated duration, and the internalization of GPR84-GFP (indicated by the white arrow heads) was observed by confocal fluorescence microscopy. Scale bars = 5 mm.
Discovery of New GPR84 Agonist
ZQ-16 Induces Other Signal Transductions by Activating GPR84. Medium-chain FFAs activated GPR84 couples primarily to a pertussis toxin-sensitive Gai/o pathway, which decreases intracellular cAMP levels (Wang et al., 2006) . ZQ-16 also induced a dose-dependent reduction of forskolinstimulated cAMP accumulation in HEK293 cells expressing GPR84, with an EC 50 value of 0.134 6 0.023 mM (Fig. 3A) , which is approximately 2.5-fold more potent than 6-OAU (EC 50 5 0.341 6 0.064 mM) (Fig. 3A) , 9-fold more potent than diindolylmethane (EC 50 5 1.11 6 0.24 mM) (Fig. 3B) , 322-fold more potent than 2-hydroxy decanoic acid (EC 50 5 40.8 6 7.3 mM) (Fig. 3C) , and 96-fold more potent than 3-hydroxy lauric acid (EC 50 5 14.2 6 5.3 mM) (Fig. 3D) . 2-Hydroxy decanoic acid and 3-hydroxy lauric acid are two endogenous agonists of GPR84 (Suzuki et al., 2013) , whereas diindolylmethane is a reported positive allosteric modulator of the receptor (Nikaido et al., 2015) .
Many GPCRs can activate the ERK1/2 pathway (Pierce et al., 2002) . Stimulation of GPR84 with 6-OAU led to phosphorylation of ERK1/2 (Fig. 4A ). Similar to 6-OAU, ZQ-16 (10 mM) also induced phosphorylation of ERK1/2 in GPR84-expressing HEK293 cells. In contrast, only phorbol-12-myristate-13-acetate, the protein kinase C activator, induced ERK1/2 phosphorylation in HEK293 cells transfected with empty vector, whereas the other compounds had no effect (Fig.  4B) . These results further confirmed that ZQ-16 is a GPR84 agonist and can induce GPR84-mediated signal transduction.
ZQ-16 Induces GPR84 Desensitization, Internalization, and b-Arrestin2 Recruitment. Receptor desensitization is a general mechanism that leads to the loss of GPCR function after repetitive agonist stimulation. We have also demonstrated 6-OAU induces GPR84 desensitization in a dose-dependent manner (Fig. 1C) . ZQ-16 also displayed a receptor-desensitization effect in the primary screen. Here, we studied ZQ-16-induced GPR84 desensitization in more detail. In contrast to DMSO control, both ZQ-16 and 6-OAU induced robust intracellular calcium elevation during the first stimulation of GPR84 (Fig. 5A, first arrow, and Fig. 5B ), again confirming that they are agonists of GPR84. After 10-minute incubation, cells were washed and restimulated with 6-OAU again (Fig. 5A, second arrow) . Only those cells prestimulated with DMSO displayed a significant augment of calcium signal, whereas prestimulation with ZQ-16 or 6-OAU led to GPR84 desensitization, i.e., a reduced calcium response at the second stimulation with 6-OAU (Fig. 5A, second arrow, and Fig. 5B) .
Following agonist binding, most GPCRs are internalized into endosomes and then sorted into either degradation or recycle pathways. GPCR internalization plays important roles in regulating the functional process of receptor desensitization (Pierce et al., 2002; Ritter and Hall, 2009; Calebiro et al., 2010) . Both the HA-and GFP-tagged GPR84 were found to mainly localize on the plasma membrane (Figs. 1A and 6) . In contrast to vehicle control (0.1% DMSO), 6-OAU and ZQ-16 (both at 10 mM) induced time-dependent formation of intracellular fluorescent granules, indicating the internalization of GPR84-GFP fusion protein (Fig. 6) .
The internalization of GPCRs is generally considered a b-arrestin-mediated process. b-Arrestins are adapter proteins that form complexes with GPCRs following agonist binding and receptor phosphorylation by G protein-coupled receptor kinases (Luttrell and Lefkowitz, 2002; Calebiro et al., 2010) . A split luciferase complementation assay (Hida et al., 2009; Hattori et al., 2013) was used to test whether ZQ-16 induces interaction between GPR84 and b-arrestin2. ELuc was split into two parts. The N terminus of ELuc was fused to b-arrestin2, and the C-terminus of ELuc was fused to GPR84. The two parts of ELuc will form a functional enzyme once GPR84 and b-arrestin2 form a complex. As shown in Fig. 7A , ZQ-16 induced a dose-dependent recruitment of b-arrestin2 toward GPR84 in HEK293 cells expressing both proteins with an EC 50 value of 0.597 6 0.055 mM, which is approximately 3-fold more potent than 6-OAU (EC 50 5 1.75 6 0.46 mM) (Fig.  7B ). These data demonstrate that ZQ-16 can induce GPR84 desensitization, internalization, and b-arrestin2 recruitment, resembling many GPCR agonists.
ZQ-16 Displays an Additive but Not Synergistic Effect with Medium-Chain Fatty Acids. Synthetic ligands may target GPCRs at the same binding site as the endogenous agonists, i.e., the orthosteric sites. Or they may target the receptor at binding regions topologically distinct from the orthosteric sites, which are called allosteric sites (Jensen and Spalding, 2004; Burford et al., 2011) . Compared with orthosteric ligands, allosteric ligands may alter the structure of the receptor from a different binding pocket and thus alter the affinity and/or potency of the native ligand. Using a calcium assay, we measured the dose-response curve of the endogenous GPR84 agonist 3-hydroxy lauric acid in the presence of various concentrations of ZQ-16. As demonstrated in Fig. 8 , ZQ-16 did not significantly left-or right-shift the dose-response curve of 3-hydroxy lauric acid (EC 50 values are 13.2 6 0.5, 17.9 6 4.6, 11.2 6 0.7, or 24.0 6 5.6 mM in the presence of 0, 20, 60, or 180 nM ZQ-16, respectively); they only caused additive effects with low concentrations of 3-hydroxy lauric acid. Although a cocrystallization study is needed to ultimately determine whether a compound binds to the orthosteric or allosteric site, our functional data suggest that ZQ-16 is more likely to be an orthosteric agonist rather than an allosteric one.
Discussion
FFARs are believed to be involved in many physiologic processes, such as glucose and lipid homeostasis, inflammation, and adiposity (Yonezawa et al., 2013) . It is of great interest to find small-molecule ligands of FFARs, which may help dissect the roles of these receptors and be developed into therapies for various metabolic and inflammatory diseases. As a member of FFARs, GPR84 is activated by medium-chain FFAs with carbon chain lengths ranging from 9 to 14, including nonanoic acid (C9), capric acid (C10), undecanoic acid (C11), lauric acid (C12), tridecanoic acid (C13), and myristic acid (C14) (Wang et al., 2006) . However, the potencies of these endogenous ligands are relatively low. The most potent GPR84 agonist reported so far is 6-OAU, with an EC 50 value of 0.5 mM (∼1 mM in our calcium assay and ∼0.3 mM in the cAMP assay) (Wang et al., 2006; Suzuki et al., 2013) . It is evident that a lack of highly potent and selective ligands of GPR84 has limited the functional characterization of this less well known FFAR and hindered the potential clinical applications. Therefore, we sought to discover new GPR84 ligands with high-throughput screening.
Typically, an agonist screen with functional cell assays only involves the direct stimulation of the cells with compounds of interest. In such a screen setup, only agonists, which stimulate positive cellular responses, will be identified. To identify antagonists, the whole library has to be screened again in a different setup. To discover both GPR84 agonists and antagonists in one primary screen, we designed a two-step protocol using the receptor-desensitization theory. In step 1, primary screen in the antagonist mode, HEK293/Ga16/GPR84 cells are pretreated with test compounds and then restimulated with 3 mM 6-OAU. Compounds that block the signal of 6-OAU may include true antagonists and agonists which induce receptor desensitization. In step 2, secondary screen in the agonist mode, the compounds that block the signal of 6-OAU are used to stimulate HEK293/Ga16/GPR84 directly, and agonists evoke calcium response while antagonists have no effect. Thus, with these two simple steps, we can identify both GPR84 agonists and antagonists in one high-throughput screen.
Using this simple protocol, we screened 160,000 compounds from the in-house chemical library using the antagonist mode, and further characterized the compounds which showed $70% inhibition of the calcium signal evoked by 6-OAU in the primary screen using the agonist mode. Both agonists and antagonists were identified from this screen. Here, we characterized in detail one agonist, ZQ-16, with a chemical structure of 2-(hexylthio)pyrimidine-4,6-diol. ZQ-16 is more potent than the currently most potent GPR84 agonist 6-OAU in both the calcium mobilization assay and the cAMP assay. ZQ-16 also activates several other GPR84-mediated signal pathways, including phosphorylation of ERK1/2 and receptor desensitization and internalization. ZQ-16 is also highly selective for GPR84 and has no activity on the other FFARs.
Taken together, ZQ-16, a potent and selective GPR84 agonist with a new scaffold, was discovered and characterized. This compound might be a valuable tool to study the functions of GPR84 in metabolic and inflammatory diseases. This compound might also serve as a starting point for structural modifications and structure-activity relationship studies in the future.
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